These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

134 related articles for article (PubMed ID: 8504663)

  • 1. Continuous infusion of pyridostigmine in the management of myasthenic crisis.
    Saltis LM; Martin BR; Traeger SM; Bonfiglio MF
    Crit Care Med; 1993 Jun; 21(6):938-40. PubMed ID: 8504663
    [No Abstract]   [Full Text] [Related]  

  • 2. Continuous infusion of pyridostigmine for myasthenic crisis.
    Nicholson J; Grant IS
    Crit Care Med; 1994 May; 22(5):895-6. PubMed ID: 8181302
    [No Abstract]   [Full Text] [Related]  

  • 3. Management of myasthenic crisis: continuous anticholinesterase infusions.
    Borel CO
    Crit Care Med; 1993 Jun; 21(6):821-2. PubMed ID: 8504646
    [No Abstract]   [Full Text] [Related]  

  • 4. Plasma pyridostigmine levels in patients with myasthenia gravis.
    Calvey TN; Chan K
    Clin Pharmacol Ther; 1977 Feb; 21(2):187-93. PubMed ID: 837637
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Steady state kinetics of pyridostigmine in myasthenia gravis.
    Sørensen PS; Flachs H; Friis ML; Hvidberg EF; Paulson OB
    Neurology; 1984 Aug; 34(8):1020-4. PubMed ID: 6540381
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Malabsorption of pyridostigmine in patients with myasthenia gravis.
    Cohan SL; Dretchen KL; Neal A
    Neurology; 1977 Mar; 27(3):299-301. PubMed ID: 557769
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Effect of polstigmine on the status of the respiratory muscles and pulmonary function in patients with myasthenia gravis].
    Radwan L; Strugalska MH; Koziorowski A
    Pneumonol Pol; 1987; 55(11-12):499-503. PubMed ID: 3444736
    [No Abstract]   [Full Text] [Related]  

  • 8. Plasma pyridostigmine levels in myasthenia gravis.
    White MC; De Silva P; Havard CW
    Neurology; 1981 Feb; 31(2):145-50. PubMed ID: 7193298
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Pyridostigmine kinetics in healthy subjects and patients with myasthenia gravis.
    Breyer-Pfaff U; Maier U; Brinkmann AM; Schumm F
    Clin Pharmacol Ther; 1985 May; 37(5):495-501. PubMed ID: 3987173
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Recovery from myasthenic crisis after use of IVIG therapy.
    Jain K; Passi GR; Rajguru M; Athle S; Gandhi DM
    Indian Pediatr; 1998 Sep; 35(9):901-3. PubMed ID: 10216601
    [No Abstract]   [Full Text] [Related]  

  • 11. Plasma concentration of pyridostigmine and effects in myastenia gravis.
    Chan K; Calvey TN
    Clin Pharmacol Ther; 1977 Nov; 22(5 Pt 1):596-601. PubMed ID: 199393
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Therapy of myasthenic crisis.
    Berrouschot J; Baumann I; Kalischewski P; Sterker M; Schneider D
    Crit Care Med; 1997 Jul; 25(7):1228-35. PubMed ID: 9233752
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Neuromuscular function and plasma drug levels in pyridostigmine treatment of myasthenia gravis.
    Breyer-Pfaff U; Schmezer A; Maier U; Brinkmann A; Schumm F
    J Neurol Neurosurg Psychiatry; 1990 Jun; 53(6):502-6. PubMed ID: 2166138
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Treatment of myasthenia gravis].
    Janda A; Brandstetter A
    Dtsch Med Wochenschr; 1986 Jul; 111(27):1081-2. PubMed ID: 3720565
    [No Abstract]   [Full Text] [Related]  

  • 15. Benefits from sustained-release pyridostigmine bromide in myasthenia gravis: results of a prospective multicenter open-label trial.
    Sieb JP; Köhler W
    Clin Neurol Neurosurg; 2010 Nov; 112(9):781-4. PubMed ID: 20663605
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The effect of neostigmine on pyridostigmine bioavailability in myasthenic patients after oral administration.
    Chan K; Davison SC; Dehghan A; Hyman N
    Methods Find Exp Clin Pharmacol; 1981; 3(5):291-6. PubMed ID: 7329157
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Renal clearance of pyridostigmine in patients with myasthenia gravis.
    Chan K; Calvey TN
    Eur Neurol; 1977; 16(1-6):69-72. PubMed ID: 615720
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Quantitative correlation between plasma pyridostigmine levels and neuromuscular function in myasthenia gravis.
    Milner-Brown HS; Mellenthin M; Sharma ML; Miller RG
    Neurology; 1987 May; 37(5):800-3. PubMed ID: 3574680
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The effect of chronic pyridostigmine administration on pyridostigmine-14C metabolism in myasthenia gravis.
    Kornfeld P; Wolf RL; Samuels AJ; Osserman KE
    Neurology; 1971 May; 21(5):550-2. PubMed ID: 5104099
    [No Abstract]   [Full Text] [Related]  

  • 20. Prescription profile of pyridostigmine use in a population of patients with myasthenia gravis.
    Machado-Alba JE; Calvo-Torres LF; Gaviria-Mendoza A; Augusto MejíA-Vélez C
    Muscle Nerve; 2017 Dec; 56(6):1041-1046. PubMed ID: 28214292
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.